As a market access consultant in Australia, Megan’s expertise spans the full product lifecycle, from early pathway mapping and burden-of-illness analyses through to NICE submissions, payer engagement materials and global medical affairs initiatives.

She has supported clients across diverse healthcare systems and payer environments to build the clinical and economic evidence required for reimbursement of novel therapies, including gene and cell therapies. Megan has particular experience in Australian reimbursement pathways, including PBAC and MSAC submissions.

Megan also holds expertise in monitoring and evaluation and evidence synthesis for life science and non-profit clients. Her work spans quantitative and qualitative methods, with a focus on producing evidence that is actionable for decision-makers.